Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nutriband Inc (NQ: NTRB )

7.390 +0.550 (+8.04%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,990
Open 7.130
Bid (Size) 7.030 (1)
Ask (Size) 7.400 (1)
Prev. Close 6.840
Today's Range 6.980 - 7.400
52wk Range 1.530 - 7.400
Shares Outstanding 6,356,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
Via ACCESSWIRE

Performance

YTD
+219.35%
+219.35%
1 Month
+35.10%
+35.10%
3 Month
+84.29%
+84.29%
6 Month
+167.75%
+167.75%
1 Year
+133.12%
+133.12%

More News

Read More
NTRB Stock Earnings: Nutriband Reported Results for Q1 2024
Via InvestorPlace
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program
Via Investor Brand Network
Exposures Product Safety
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
Via ACCESSWIRE
NTRB Stock Earnings: Nutriband Reported Results for Q4 2023
Via InvestorPlace
Nutriband Inc. Announces $8.4M Private Placement
Via ACCESSWIRE
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report
Via Investor Brand Network
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
Via ACCESSWIRE
BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session
Via Investor Brand Network
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Names Seasoned Business Leader to Board of Directors
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Featured in Upcoming RedChip Small, Big Money(TM) Show
Via Investor Brand Network
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Fentanyl Scourge: Nutriband Inc.’s (NASDAQ: NTRB) New Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Closes $8.4M Private Placement
Via Investor Brand Network
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
Via ACCESSWIRE
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Enters Exclusive Supplier Agreement with Major Sports Brand Licensee
Via Investor Brand Network
Topics Supply Chain
Exposures Supply Chain
Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic
Via Investor Brand Network
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Into Private Placement Agreements to Raise Funds for Development of AVERSA Fentanyl
Via Investor Brand Network
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.